Health Claims Substantiation
Evidence standards and regulatory controls for efficacy, safety, and comparative claims made for OTC medicines, cosmetics, supplements, and consumer health products.
Foresight tracks Health Claims Substantiation developments and surfaces the alerts most likely to matter before they turn into missed deadlines, recalls, or escalation work.
Not ready for a trial? Take the 3-minute readiness assessment
Current activity
Cooling
83% below the prior 8-week baseline
3-month trend
Latest alerts below
Last updated
7 May 2026, 20:01
Latest Health Claims Substantiation alerts
The most recent regulatory and guidance signals tracked by Foresight
Taiwan MOHW Proposes Revised Evaluation Method for Lipid-Regulating Health Food Claims
Taiwan’s Ministry of Health and Welfare has released a draft revision of the clinical evaluation method for lipid‑regulating health food claims and opened a 60‑day public consultation from its May 2026 gazette publication. If adopted, the clarified standards for trial design, lipid endpoints, statistical power and allowable claim wording will raise the evidentiary bar for companies seeking lipid‑regulating health food approvals in Taiwan.
TaiwanUK ASA Upholds Complaint Against Garnier ‘Clinically Proven’ Hyperpigmentation Claim
In April 2026 the UK Advertising Standards Authority upheld a complaint against L’Oréal UK over a Garnier Vitamin Cg Serum ad claiming it was “clinically proven” to reduce hyperpigmentation in two weeks, finding the supporting clinical trial and ingredient data too weak and unrepresentative of typical UK use. This ruling reinforces that cosmetics and personal care brands making “clinically proven” efficacy claims in the UK must hold robust, well‑designed and locally relevant clinical evidence, or risk ads being banned and future campaigns forced to tighten claim wording and substantiation.
United KingdomBavarian Higher Administrative Court Confirms OMEGAlife Omega-3 Product Is a Food Supplement, Not a Medicinal Product
The Bavarian Higher Administrative Court ruled in March 2026 that Omega-3 supplements with nutrient levels achievable through a standard diet must be classified as food supplements rather than medicinal products. This decision sets a strict precedent for functional medicinal status in Germany, increasing the burden on manufacturers to demonstrate unique metabolic effects to secure pharmaceutical classification and reimbursement.
GermanyJapan CAA Confirms 31 March 2026 Reporting Deadline and Enforcement for Functional Claims Foods
Japan has confirmed a strict March 2026 deadline for mandatory self-check reporting on functional claims foods to ensure manufacturing and quality compliance. Failure to report will trigger public database flagging and the loss of health claim status, requiring immediate internal audits to protect market access and brand reputation.
JapanChina SAMR Orders Half-Year Cleanup of Prompt Language in Advertising
China has initiated a six-month nationwide enforcement campaign targeting misleading advertising disclosures and inadequate risk warnings for complex and regulated products. Businesses should prioritize auditing marketing materials to ensure statutory warnings and limiting conditions are prominent and substantiated to avoid significant administrative penalties.
ChinaUS FDA Issues Online Advisory Letter to Divine Rx Nutrition for Disease-Claim Supplements
The FDA issued an advisory letter to Divine Rx Nutrition for marketing supplements with unapproved disease-treatment claims, classifying them as illegal new drugs. This action signals continued aggressive enforcement against online health-claim violations, requiring firms to strictly audit digital marketing and labeling to mitigate regulatory risk.
United StatesUS FDA Issues Online Advisory Letter to Bodynplant Over Unapproved Serious Disease Treatment Claims
The US FDA has intensified enforcement against online retailers marketing unapproved products with claims to treat serious diseases. Companies must audit digital marketing and labeling to ensure health claims do not trigger regulatory reclassification, risking enforcement and public blacklisting.
United StatesNetherlands Council Of State Refers Food Supplement–Medicine And Online Review Questions To CJEU (ECLI:NL:RVS:2026:1651)
The Dutch Council of State has referred questions to the CJEU to define the legal boundary between food supplements and medicinal products in online retail. This ruling will determine if consumer reviews and digital presentation can trigger pharmaceutical-level liability, reshaping compliance and moderation risks for health product platforms.
Netherlands
European UnionBrazilian Chamber Working Group Backs Urgent Bills to Tighten Sanitary Control of Dietary Supplements
Brazil is fast-tracking legislation to significantly tighten sanitary controls and increase penalties for dietary supplement fraud and misleading advertising. Businesses should prepare for mandatory QR-code traceability, stricter liability for online marketplaces, and the potential criminalization of regulatory non-compliance.
BrazilUK Department of Health and Social Care Updates ACBS Application Guidance and Submission Deadlines
The UK has updated submission deadlines and transitioned to a digital-only application process for the Advisory Committee on Borderline Substances through 2027. Manufacturers of specialized medical foods and supplements must align product development and reimbursement strategies with these fixed windows to ensure uninterrupted NHS market access.
United KingdomBrazil ANVISA Seizes Irregular Health Products At Mercado Livre Warehouse
Brazil’s ANVISA has escalated enforcement against irregular health and cosmetic products, conducting a major seizure at a leading e-commerce fulfillment center in March 2026. This move establishes a precedent for platform-level accountability, requiring manufacturers and distributors to ensure strict compliance with local registration and labeling standards to avoid supply chain disruptions.
BrazilVietnam Abolishes Pre-Market Approval for Cosmetic Advertising
Vietnam has transitioned from pre-market approval to a post-market surveillance regime for cosmetic advertising as of February 2026. Companies must now strengthen internal compliance and maintain robust claim-substantiation files to mitigate enforcement risks under the general advertising framework.
VietnamJapan Consumer Affairs Agency Publishes Settlement of Consumer Group Injunction on LISTERINE “No.1” Bactericidal Claims
Japan's Consumer Affairs Agency has finalized a settlement regarding misleading superlative marketing and efficacy claims on consumer product labeling. This enforcement underscores the need for clear substantiation of performance rankings to avoid misrepresentation risks and potential injunctions from consumer advocacy groups.
JapanColorado Bill SB26-066 Would Regulate Compounded Weight-Loss Medications
Colorado is advancing legislation to mandate strict manufacturing standards and safety labeling for non-FDA-approved compounded weight-loss medications. Operators must implement rigorous ingredient traceability and disclosure protocols to avoid substantial per-dose fines and potential loss of business licenses.
United StatesUS District Court (New Jersey) Dismisses PFAS Consumer Suit Against Band-Aid For Lack Of Standing
A US Federal Court dismissed a consumer class action alleging PFAS contamination in bandages due to a lack of concrete injury or specific misrepresentation. This ruling reinforces a high evidentiary bar for PFAS litigation based on general safety marketing and economic loss theories without proof of actual harm.
United StatesEFSA NDA Panel Finds Insufficient Evidence for Anxiofit‑1 Article 14 Health Claim on Anxiety Reduction
EFSA has rejected a disease risk-reduction health claim for Anxiofit-1, citing insufficient clinical evidence to link the botanical extract with reduced anxiety. This decision reinforces the high evidentiary bar for Article 14 claims, signaling that manufacturers must provide robust long-term efficacy data and clear mechanisms of action to secure EU market authorization.
European UnionEU Parliament Questions Commission on Energy Powders for Inhalation (P-000828/2026)
The European Commission has been formally challenged to clarify the regulatory status and safety of inhaled energy powders that currently evade traditional food and drug classifications. Manufacturers of novel stimulant delivery systems should anticipate increased market surveillance and potential legislative action to address consumer safety risks and marketing loopholes.
European UnionBrazil Anvisa Orders Seizure of Palmito Lemos Palm-Heart Products and Recall of Melatonin Sublingual Drops
Brazil's ANVISA has mandated the immediate seizure of Palmito Lemos canned palm hearts and the recall of specific melatonin supplements due to critical manufacturing and safety violations. These enforcement actions highlight intensified market surveillance on food safety and supplement claims, requiring immediate supply chain intervention to mitigate legal and reputational risks.
BrazilKorea Cosmetics Association Announces Planned Amendment to Cosmetics Act on Labelling and Environmental Claims
South Korea is advancing an amendment to the Cosmetics Act to tighten standards for product labeling and environmental or efficacy claims. Businesses should prepare for more rigorous substantiation requirements for green marketing and performance claims to ensure continued market access and compliance.
South KoreaKorea MFDS Outlines 2027 Periodic Re-evaluation Programme For Health Functional Food Ingredients
South Korea has initiated the 2027 re-evaluation cycle for 31 health functional food ingredients, with mandatory data submissions due by late 2026. Companies must prepare robust safety and efficacy substantiation to mitigate risks of revised health claims, restricted usage, or potential market withdrawal.
South KoreaNot a newsletter. Not a feed.
Structured intelligence mapped to your business.
These are just a few of the most recent Health Claims Substantiation alerts. Foresight tracks every jurisdiction, every day — and surfaces only what affects your portfolio, with full citations and evidence.
Start free trialFrequently asked questions
Everything you need to know about Foresight's regulatory intelligence platform
Still have questions? Get in touch with our team
Join 3,500+ professionals staying ahead
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at
